Dr. Marc P. Bonaca, M.D.
Cardiology (Cardiovascular Disease Physician)
12605 E 16th Ave
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Connecticut School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 84
Licensed in Colorado since 2019, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Connecticut School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
CO license DR.0061700 (first issued 2019; active) · MA license 226729
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Colorado Hospital Authority Aurora, CO
Medical groups
- University Physicians Incorporated (3,215 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 84
- Services billed
- 173
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 52 | 20 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 30 | 30 |
| Established patient office or other outpatient visit, 30-39 minutes | 13 | 11 |
| Hospital discharge day management, more than 30 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 122 payments worth $209,331 in total to this clinician.
| Novo Nordisk As | $89,519 |
|---|---|
| AstraZeneca UK Limited | $33,737 |
| Novartis Pharmaceuticals Corporation | $25,355 |
| Regeneron Pharmaceuticals, Inc. | $19,072 |
| Merck Sharp & Dohme LLC | $12,809 |
| E.r. Squibb & Sons, L.l.c. | $7,163 |
| Novo Nordisk Inc | $6,488 |
| Eli Lilly and Company | $2,800 |
| Consulting Fee | $169,537 |
|---|---|
| Travel and Lodging | $34,820 |
| Food and Beverage | $2,980 |
| Compensation for services other than consulting (speaking, faculty) | $1,995 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk As Nov 19, 2025 | Consulting Fee Cardiovascular | $15,504 |
| Novo Nordisk As Apr 24, 2025 | Consulting Fee | $15,504 |
| Novartis Pharmaceuticals Corporation Nov 9, 2025 | Consulting Fee | $10,825 |
| Novo Nordisk As Nov 8, 2025 | Consulting FeeCompany’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $10,401 |
| Novo Nordisk As Nov 19, 2025 | Travel and Lodging Cardiovascular · travel to Copenhagen, Denmark · in-kind | $9,830 |
| Novo Nordisk As Sep 16, 2025 | Travel and Lodging Diabetes · travel to Vienna, Austria · in-kind | $9,821 |
| Novo Nordisk As Sep 16, 2025 | Consulting Fee Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $9,224 |
| Novo Nordisk As Apr 24, 2025 | Travel and Lodging travel to København, Denmark · in-kind | $9,211 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Consulting Fee | $7,425 |
| AstraZeneca UK Limited Sep 12, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $6,175 |
All 92 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca UK Limited Dec 24, 2025 | Consulting Fee | $1,300 |
| AstraZeneca UK Limited Dec 16, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $2,925 |
| Boehringer Ingelheim International GmbH Dec 7, 2025 | Travel and Lodging travel to Washington DC, DC · in-kind | $1,129 |
| Boehringer Ingelheim International GmbH Dec 7, 2025 | Travel and Lodging travel to Washington DC, DC · in-kind | $526 |
| Boehringer Ingelheim International GmbH Dec 7, 2025 | Travel and Lodging travel to Washington DC, DC · in-kind | $259 |
| AstraZeneca UK Limited Dec 3, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,950 |
| Merck Sharp & Dohme LLC Dec 3, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $1,525 |
| AstraZeneca UK Limited Nov 27, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,300 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Consulting Fee | $7,425 |
| Regeneron Pharmaceuticals, Inc. Nov 21, 2025 | Consulting Fee | $1,087 |
| Novo Nordisk As Nov 19, 2025 | Consulting Fee Cardiovascular | $15,504 |
| Novo Nordisk As Nov 19, 2025 | Travel and Lodging Cardiovascular · travel to Copenhagen, Denmark · in-kind | $9,830 |
| Novo Nordisk As Nov 19, 2025 | Consulting Fee Cardiovascular Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $1,570 |
| Novo Nordisk As Nov 19, 2025 | Travel and Lodging Cardiovascular · travel to Copenhagen, Denmark · in-kind | $705 |
| Novo Nordisk As Nov 19, 2025 | Travel and Lodging Cardiovascular · travel to Copenhagen, Denmark · in-kind | $169 |
| Novartis Pharmaceuticals Corporation Nov 9, 2025 | Consulting Fee | $10,825 |
| Novartis Pharmaceuticals Corporation Nov 9, 2025 | Travel and Lodging travel to NEW ORLEANS, LA · in-kind | $329 |
| Novo Nordisk As Nov 8, 2025 | Consulting FeeCompany’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $10,401 |
| Lilly USA, LLC Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,400 |
| Merck Sharp & Dohme LLC Nov 5, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $104 |
| Merck Sharp & Dohme LLC Nov 5, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $101 |
| Merck Sharp & Dohme LLC Nov 5, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $101 |
| Csl Behring Nov 1, 2025 | Consulting Fee | $1,188 |
| E.r. Squibb & Sons, L.l.c. Oct 28, 2025 | Consulting Fee | $2,865 |
| AstraZeneca UK Limited Oct 22, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $2,925 |
| E.r. Squibb & Sons, L.l.c. Oct 6, 2025 | Consulting Fee | $1,433 |
| AstraZeneca UK Limited Oct 1, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $3,250 |
| AstraZeneca UK Limited Sep 25, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,550 |
| Lilly USA, LLC Sep 22, 2025 | Consulting Fee ZEPBOUND · Obesity Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,400 |
| Merck Sharp & Dohme LLC Sep 17, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $4,800 |
| Merck Sharp & Dohme LLC Sep 17, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $156 |
| Merck Sharp & Dohme LLC Sep 17, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $151 |
| Merck Sharp & Dohme LLC Sep 17, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $151 |
| Merck Sharp & Dohme LLC Sep 17, 2025 | Travel and Lodging travel to Madrid, Spain Company’s descriptionPayment made to Third Party Organization not to Physician. | $150 |
| Novo Nordisk As Sep 16, 2025 | Travel and Lodging Diabetes · travel to Vienna, Austria · in-kind | $9,821 |
| Novo Nordisk As Sep 16, 2025 | Consulting Fee Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $9,224 |
| Novo Nordisk As Sep 16, 2025 | Travel and Lodging Diabetes · travel to Vienna, Austria · in-kind | $1,298 |
| Novo Nordisk As Sep 16, 2025 | Compensation for services other than consulting (speaking, faculty) Diabetes | $595 |
| Novo Nordisk As Sep 16, 2025 | Travel and Lodging Diabetes · travel to Vienna, Austria · in-kind | $211 |
| AstraZeneca UK Limited Sep 12, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $6,175 |
| AstraZeneca UK Limited Sep 12, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,950 |
| AstraZeneca UK Limited Sep 8, 2025 | Consulting Fee | $1,950 |
| Novartis Pharmaceuticals Corporation Aug 29, 2025 | Consulting Fee | $5,850 |
| Regeneron Pharmaceuticals, Inc. Aug 22, 2025 | Consulting Fee | $1,087 |
| Regeneron Pharmaceuticals, Inc. Aug 22, 2025 | Consulting Fee | $1,087 |
| Regeneron Pharmaceuticals, Inc. Aug 22, 2025 | Consulting Fee | $1,087 |
| Regeneron Pharmaceuticals, Inc. Aug 22, 2025 | Consulting Fee | $815 |
| Regeneron Pharmaceuticals, Inc. Aug 22, 2025 | Consulting Fee | $544 |
| Eli Lilly and Company Aug 18, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,750 |
| Csl Behring Jul 14, 2025 | Consulting Fee | $1,584 |
| AstraZeneca Pharmaceuticals LP Jul 2, 2025 | Consulting Fee LOKELMA · Cardiovascular and Metabolism Company’s descriptionResearch Related Service | $2,400 |
| AstraZeneca UK Limited Jun 25, 2025 | Consulting Fee | $5,200 |
| Merck Sharp & Dohme LLC Jun 25, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $104 |
| Merck Sharp & Dohme LLC Jun 25, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $101 |
| Merck Sharp & Dohme LLC Jun 25, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $101 |
| Eli Lilly and Company Jun 16, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,050 |
| E.r. Squibb & Sons, L.l.c. Jun 5, 2025 | Consulting Fee | $2,865 |
| Merck Sharp & Dohme LLC May 5, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $207 |
| Merck Sharp & Dohme LLC May 5, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $201 |
| Merck Sharp & Dohme LLC May 5, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $201 |
| Regeneron Pharmaceuticals, Inc. May 2, 2025 | Consulting Fee | $3,261 |
| Regeneron Pharmaceuticals, Inc. May 2, 2025 | Consulting Fee | $2,174 |
| Novo Nordisk Inc Apr 25, 2025 | Consulting Fee Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $1,963 |
| Novo Nordisk Inc Apr 25, 2025 | Consulting Fee Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $393 |
| Novo Nordisk As Apr 24, 2025 | Consulting Fee | $15,504 |
| Novo Nordisk As Apr 24, 2025 | Travel and Lodging travel to København, Denmark · in-kind | $9,211 |
| Novo Nordisk As Apr 24, 2025 | Consulting Fee | $785 |
| Novo Nordisk As Apr 24, 2025 | Travel and Lodging travel to København, Denmark · in-kind | $542 |
| Novo Nordisk As Apr 24, 2025 | Travel and Lodging travel to København, Denmark · in-kind | $366 |
| Amgen Inc. Apr 22, 2025 | Consulting Fee | $754 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $207 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $201 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $201 |
| Regeneron Pharmaceuticals, Inc. Apr 18, 2025 | Consulting Fee | $1,466 |
| Regeneron Pharmaceuticals, Inc. Apr 18, 2025 | Consulting Fee | $977 |
| Novo Nordisk Inc Apr 10, 2025 | Consulting Fee Victoza · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $3,925 |
| Regeneron Pharmaceuticals, Inc. Apr 4, 2025 | Consulting Fee | $1,954 |
| Novo Nordisk As Apr 1, 2025 | Consulting Fee Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $3,140 |
| Merck Sharp & Dohme LLC Apr 1, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $1,220 |
| Regeneron Pharmaceuticals, Inc. Mar 21, 2025 | Consulting Fee | $977 |
| Regeneron Pharmaceuticals, Inc. Mar 21, 2025 | Consulting Fee | $902 |
| Regeneron Pharmaceuticals, Inc. Mar 21, 2025 | Consulting Fee | $733 |
| Regeneron Pharmaceuticals, Inc. Mar 21, 2025 | Consulting Fee | $489 |
| Merck Sharp & Dohme LLC Mar 12, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $207 |
| Merck Sharp & Dohme LLC Mar 12, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $201 |
| Merck Sharp & Dohme LLC Mar 12, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $201 |
| Novartis Pharmaceuticals Corporation Mar 7, 2025 | Consulting Fee LEQVIO · Cardiology/Vascular Diseases | $450 |
| Merck Sharp & Dohme LLC Feb 10, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $915 |
| Janssen Scientific Affairs, LLC Feb 3, 2025 | Consulting Fee | $600 |
| Merck Sharp & Dohme LLC Jan 27, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $610 |
| Janssen Global Services, LLC Jan 14, 2025 | Travel and Lodging travel to WASHINGTON, DC | $275 |
| Merck Sharp & Dohme LLC Jan 13, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $610 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $2,100 in research payments for these studies, mostly to the institutions running them.
- VICTORION-1 PREVENT
Novartis Pharma AG
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.